Evaluating the role of PET/CT scans in liver transplant candidates with liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prognostic value of negative 18FDG PET/CT scans in patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation. It will include adult patients aged 18 to 80 years who are discussed for potential liver transplantation at six Belgian centers. The study will create a secured, anonymized database to track patient outcomes and determine the effectiveness of using PET/CT imaging in selecting candidates based on the Milan criteria. The goal is to improve patient selection for liver transplantation and ultimately enhance survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HepatoCellular Carcinoma
* Liver transplant candidate after multidisciplinary disccuss

Exclusion Criteria:

* Patients \< 18y or \> 80yr old
* Patients considered contra-indicated (CI) for LT due to non-liver-related medical problems (age, other cancer, psychiatric disease, uncontrolled infection, no compliance, active alcohol abuse, cardiac CI, pulmonary CI, surgical CI, other medical CI);
* Patients contra-indicated for LT due to the HCC: extra-hepatic metastases (M+), lymphatic involvement (N+), macro-vascular invasion.

Where it's running

• University Hospital, Antwerp
  Antwerp, Belgium Recruiting
• Free University of Brussels
  Brussels, Belgium Recruiting
• University Hospital, Ghent
  Ghent, Belgium Recruiting
• Catholic University of Louvain
  Leuven, Belgium Recruiting
• Leuven University hospital
  Leuven, Belgium Recruiting
• ULiège
  Liège, Belgium Recruiting

Study contacts

• Study coordinator: Olivier Detry, MD PhD
• Email: olivier.detry@chuliege.be
• Phone: 003242844757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

• GLP-1 RA plus standard treatment in first-line metastatic GI cancers

  This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.